These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 20721826)

  • 1. The formulation and immunogenicity of therapeutic proteins: Product quality as a key factor.
    Richard J; Prang N
    IDrugs; 2010 Aug; 13(8):550-8. PubMed ID: 20721826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The challenges of immunogenicity in developing biosimilar products.
    Wadhwa M; Thorpe R
    IDrugs; 2009 Jul; 12(7):440-4. PubMed ID: 19579165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein formulation and fill-finish operations.
    Patro SY; Freund E; Chang BS
    Biotechnol Annu Rev; 2002; 8():55-84. PubMed ID: 12436915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aggregates in monoclonal antibody manufacturing processes.
    Vázquez-Rey M; Lang DA
    Biotechnol Bioeng; 2011 Jul; 108(7):1494-508. PubMed ID: 21480193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The immunogenicity of biopharmaceuticals. Lessons learned and consequences for protein drug development.
    Patten PA; Schellekens H
    Dev Biol (Basel); 2003; 112():81-97. PubMed ID: 12762507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity of therapeutic proteins. Part 1: impact of product handling.
    Sharma B
    Biotechnol Adv; 2007; 25(3):310-7. PubMed ID: 17336479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current perspectives on stability of protein drug products during formulation, fill and finish operations.
    Rathore N; Rajan RS
    Biotechnol Prog; 2008; 24(3):504-14. PubMed ID: 18484778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity of therapeutics: a matter of efficacy and safety.
    Nechansky A; Kircheis R
    Expert Opin Drug Discov; 2010 Nov; 5(11):1067-79. PubMed ID: 22827745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid excipients and delivery systems for pharmaceutical development: a regulatory perspective.
    Chen ML
    Adv Drug Deliv Rev; 2008 Mar; 60(6):768-77. PubMed ID: 18077051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies for preclinical immunogenicity assessment of protein therapeutics.
    Stas P; Lasters I
    IDrugs; 2009 Mar; 12(3):169-73. PubMed ID: 19333897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biopharmaceutical challenges associated with drugs with low aqueous solubility--the potential impact of lipid-based formulations.
    O'Driscoll CM; Griffin BT
    Adv Drug Deliv Rev; 2008 Mar; 60(6):617-24. PubMed ID: 18155800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimizing immunogenicity of biopharmaceuticals by controlling critical quality attributes of proteins.
    van Beers MM; Bardor M
    Biotechnol J; 2012 Dec; 7(12):1473-84. PubMed ID: 23027660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein-excipient interactions: mechanisms and biophysical characterization applied to protein formulation development.
    Kamerzell TJ; Esfandiary R; Joshi SB; Middaugh CR; Volkin DB
    Adv Drug Deliv Rev; 2011 Oct; 63(13):1118-59. PubMed ID: 21855584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunological mechanism underlying the immune response to recombinant human protein therapeutics.
    Sauerborn M; Brinks V; Jiskoot W; Schellekens H
    Trends Pharmacol Sci; 2010 Feb; 31(2):53-9. PubMed ID: 19963283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors influencing the immunogenicity of therapeutic proteins.
    Schellekens H
    Nephrol Dial Transplant; 2005 Jun; 20 Suppl 6():vi3-9. PubMed ID: 15958824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Introductory note to the three-part series of papers by Basant Sharma on: immunogenicity of therapeutic proteins: how to assess and the role of pharmaceutical quality.
    Trouvin JH
    Biotechnol Adv; 2007; 25(3):307-9. PubMed ID: 17321095
    [No Abstract]   [Full Text] [Related]  

  • 17. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products.
    Mire-Sluis AR; Barrett YC; Devanarayan V; Koren E; Liu H; Maia M; Parish T; Scott G; Shankar G; Shores E; Swanson SJ; Taniguchi G; Wierda D; Zuckerman LA
    J Immunol Methods; 2004 Jun; 289(1-2):1-16. PubMed ID: 15251407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity of therapeutic proteins. Part 3: impact of manufacturing changes.
    Sharma B
    Biotechnol Adv; 2007; 25(3):325-31. PubMed ID: 17337334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-mediated side effects of recombinant proteins.
    Frost H
    Toxicology; 2005 Apr; 209(2):155-60. PubMed ID: 15767028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality attributes of recombinant therapeutic proteins: an assessment of impact on safety and efficacy as part of a quality by design development approach.
    Eon-Duval A; Broly H; Gleixner R
    Biotechnol Prog; 2012; 28(3):608-22. PubMed ID: 22473974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.